What is the primary therapeutic purpose of Dornase Alfa in patients with Cystic Fibrosis?

Dornase Alfa is a recombinant form of human DNase that specifically targets the thick, viscous mucus characteristic of Cystic Fibrosis. The primary therapeutic purpose of this medication is to enhance mucus clearance. In patients with Cystic Fibrosis, the accumulation of DNA from degraded white blood cells contributes to the thickness of mucus in the airways. By breaking down this extracellular DNA, Dornase Alfa reduces the viscosity of the mucus, making it easier for patients to expel the mucus through coughing or other means. This improves lung function and helps to decrease the risk of lung infections related to trapped mucus.

While reducing inflammation, managing pain, and addressing infections are important considerations in the overall treatment plan for Cystic Fibrosis, the main role of Dornase Alfa is specifically to facilitate the clearance of mucus. Thus, its primary function is to enhance mucus clearance effectively.